{"id":"W2560046425","doi":"10.1182/blood.v114.22.3286.3286","title":"Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Tyrosine-kinase inhibitor; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003513761,0.0005158839,0.00134937,0.0003376617,0.0002513638,0.000718623,0.0002895553,0.0004930673,0.001197095],"category_scores_gemma":[0.00176726,0.0002362973,0.001137165,0.0005215021,0.0003038907,0.0005482069,0.0004739558,0.0007503129,0.0002375859],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005225744,"about_ca_system_score_gemma":0.0007390552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006724256,"about_ca_topic_score_gemma":0.001906842,"domain_scores_codex":[0.9989722,0.0006173283,0.0001091013,0.00009330011,0.0001170334,0.00009111632],"domain_scores_gemma":[0.9982085,0.0003937323,0.0005999494,0.000111563,0.0001580891,0.000528031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6475947,0.008963594,0.2752107,0.001299119,0.006878229,0.0004647443,0.0003043291,0.0009436708,0.008742131,0.000147827,0.003095951,0.04635503],"study_design_scores_gemma":[0.190599,0.1733944,0.617043,0.0001573773,0.005282195,0.001263079,0.0002200342,0.001165893,0.002565825,0.0001563312,0.008088216,0.00006480148],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946945,0.00287429,0.0001072058,0.0001013717,0.00002217271,0.0003703999,0.001145587,0.000006139983,0.0006784326],"genre_scores_gemma":[0.9949796,0.001099389,0.0002778544,0.0003226433,0.00008104699,0.0003257117,0.002533723,0.000003731562,0.0003763342],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003513761,"threshold_uncertainty_score":0.01858282,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05427079988921533,"score_gpt":0.3957849007024577,"score_spread":0.3415141008132423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}